Back to today’s briefing

Story perspectives

Novo Nordisk Sues Hims Over Compounded Weight Loss Pill

2/12/2026

34 7 Full Breakdown

Summary

Story summary

Novo Nordisk filed a patent-infringement lawsuit against Hims & Hers on February 9 over its $49 compounded semaglutide pill.
The suit marks Novo Nordisk's first U.S. patent case against a compounding pharmacy.
Novo alleges Hims infringed its patents by selling compounded semaglutide without permission.
The FDA has indicated it will tighten regulations on compounded GLP-1 drugs.
The outcome could significantly impact the U.S. weight loss drug market.

History

Historical Context

The U.S. Patent Act of 1952 established a comprehensive framework for patent protection, codifying requirements for non-obviousness and enhancing rights for inventors. This legislation spurred investment in pharmaceuticals, contributing to a market valued at $1.3 trillion in 2021. Novo Nordisk's recent lawsuit against Hims & Hers highlights ongoing disputes over patent rights, particularly in the competitive weight loss drug sector.

1 of 2

Story summary

Novo Nordisk filed a patent-infringement lawsuit against Hims & Hers on February 9 over its $49 compounded semaglutide pill.
The suit marks Novo Nordisk's first U.S. patent case against a compounding pharmacy.
Novo alleges Hims infringed its patents by selling compounded semaglutide without permission.
The FDA has indicated it will tighten regulations on compounded GLP-1 drugs.
The outcome could significantly impact the U.S. weight loss drug market.

1 / 2